A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer

Enzalutamide (ENZ) is a second-generation androgen receptor (AR) antagonist used for the treatment of castration-resistant prostate cancer (CRPC) and reportedly prolongs survival time within a year of starting therapy. However, CRPC patients can develop ENZ resistance (ENZR), mainly driven by abnorm...

Full description

Bibliographic Details
Published in:	Acta Pharmaceutica Sinica B
Main Authors:	Yan Li, Ya Chu, Guangjiang Shi, Xiaobin Wang, Wanli Ye, Chun Shan, Dajia Wang, Di Zhang, Wei He, Jingwei Jiang, Shuqian Ma, Yuhong Han, Zhili Zhao, Shijia Du, Zhen Chen, Zhiyu Li, Yong Yang, Chen Wang, Xi Xu, Hongxi Wu
Format:	Article
Language:	English
Published:	Elsevier 2022-11-01
Subjects:	Drug resistance Enzalutamide Castration-resistant prostate cancer Androgen receptor splice variant 7 Heterodimers Degradation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211383522002106

Similar Items

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
by: Xiangyun You, et al.
Published: (2023-04-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01)

MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway
by: Shengfeng Zheng, et al.
Published: (2024-10-01)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
by: Nair Lopes, et al.
Published: (2021-08-01)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
by: Takuya Tsujino, et al.
Published: (2023-10-01)

THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
by: Zhe Hong, et al.
Published: (2021-07-01)

Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer
by: Marcus Moses, MS, et al.
Published: (2020-01-01)

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
by: Meng Wu, et al.
Published: (2023-01-01)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
by: Taro Iguchi, et al.
Published: (2019-04-01)

Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer
by: MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming
Published: (2025-02-01)

Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
by: Luo J, et al.
Published: (2016-11-01)

Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review
by: Zineddine Belabaci, et al.
Published: (2025-05-01)

Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer
by: Shiv Verma, et al.
Published: (2020-11-01)

Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
by: Xu Wen, et al.
Published: (2023-05-01)

Possibilities of treatment of patients with castrationrefractory prostate cancer using enzalutamide
by: B. Ya. Alekseyev, et al.
Published: (2019-12-01)

Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study
by: Sung Hee Lim, et al.
Published: (2024-03-01)

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
by: Ali Alkan, et al.
Published: (2021-09-01)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
by: Namrata Khurana, et al.
Published: (2020-01-01)

ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer
by: Jinpeng Cen, et al.
Published: (2025-06-01)

Correction: ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer
by: Jinpeng Cen, et al.
Published: (2025-06-01)

Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases
by: S. V. Popov
Published: (2020-12-01)

MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC
by: Yuanyuan Wang, et al.
Published: (2024-04-01)

Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
by: Mercedes Marín-Aguilera, et al.
Published: (2020-01-01)

Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report
by: Tomas Pokrivcak, et al.
Published: (2024-04-01)

Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy
by: Wenjun Jiang, et al.
Published: (2020-03-01)

Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Neal Shore, et al.
Published: (2024-10-01)

Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use
by: Cheng-Kuang Yang, et al.
Published: (2023-04-01)

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide
by: Masaki Hirabatake, et al.
Published: (2022-05-01)

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
by: Wei Zhang, et al.
Published: (2017-01-01)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
by: Shigetomo Yamada, et al.
Published: (2022-03-01)

Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival
by: Ritesh P. Bhole, et al.
Published: (2023-12-01)

Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate
by: Ondřej Fiala, et al.
Published: (2024-01-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
by: Timothy C. Wright, et al.
Published: (2021-07-01)

DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER
by: S. V. MISHUGIN, et al.
Published: (2016-12-01)

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
by: Zhe Zhu, et al.
Published: (2024-11-01)

Regulation of androgen receptor variants in prostate cancer
by: Yezi Zhu, et al.
Published: (2020-07-01)

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
by: Tianfang Ma, et al.
Published: (2021-02-01)

Sequential Androgen Receptor Pathway Inhibitor in Prostate Cancer: Piling-Up The Benefits or a Case for Cross-Resistance?
by: Bertrand Tombal
Published: (2014-11-01)